EX-FILING FEES 6 ex107.htm EXHIBIT 107

 

Exhibit 107

 

Calculation of Filing Fee Tables

FORM F-1

…………...

(Form Type)

Biodexa Pharmaceuticals PLC

………………………………………………………..

(Exact Name of Registrant as Specified in its Charter)

Table 1: Newly Registered Securities

 

 

 

 

Security
Type

Security Class Title(1)

Fee
Calculation
or Carry
Forward
Rule

Amount
Registered(2)

Proposed
Maximum
Offering
Price Per
Unit

Maximum
Aggregate
Offering
Price(3)

Fee Rate

Amount of
Registration
Fee

Fees to Be Paid Equity Ordinary Shares, £0.001 per share  457(c) 1,283,541,200 $0.003 $3,850,623.60 $0.00014760 $568.35
    Total Offering Amounts      

$   3,850,623.60

  

$   568.35

    Total Fees Previously Paid           --
    Total Fee Offsets          

--

    Net Fee Due          

$   568.35

 

(1)American Depositary Shares, or Depositary Shares, issuable upon the deposit of the ordinary shares, nominal value £0.001 per share, or Ordinary Shares, registered hereby have been registered under a separate Registration Statement on Form F-6 (File No. 333-207186), as amended. Each American Depositary Share represents 400 Ordinary Shares.
(2)This registration statement also includes an indeterminate number of shares underlying the Depositary Shares that may become offered, issuable or sold to prevent dilution resulting from stock splits, stock dividends and similar transactions, which are included pursuant to Rule 416 under the Securities Act of 1933, as amended.
(3)Estimated solely for purposes of calculating the registration fee in accordance with Rule 457(c) under the Securities Act of 1933, as amended, based on the average of the high and low sales price of the Depositary Shares on the NASDAQ Capital Market on March 14, 2024, divided by 400 (to give effect to the 1:400 ratio of Depositary Shares to Ordinary Shares).
(4)Consists of (1) 89,978,800 Ordinary Shares represented by 224,947 Depositary Shares issued in a private placements in December 2023, and (2) 910,020,000 Ordinary Shares represented by 2,275,050 Depositary Shares, issuable upon the exercise of pre-funded warrants issued in a private placement in December 2023.